p16INK4a promoter methylation and protein expression in breast fibroadenoma and carcinoma
Open Access
- 1 December 2004
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 114 (3) , 414-421
- https://doi.org/10.1002/ijc.20771
Abstract
The potential role of p16INK4a methylation in breast cancer is controversial whereas there are no data on fibroadenoma. To assess if inactivation of p16INK4a by promoter hypermethylation occurs in this hyperproliferative benign breast lesion or, on the contrary, it is strictly related to the carcinogenic process, we have tested the different histological components of 15 cases of fibroadenoma and the intraductal and infiltrating components of 15 cases of carcinoma and their adjacent non-tumoral epithelium. All samples were obtained by laser-assisted microdissection. The relationship between promoter methylation status, immunohistochemical protein expression and ki67 proliferative activity was evaluated for each lesion. Our data demonstrate that hypermethylation of p16INK4a promoter is a common event occurring at similar frequency in all the different histological areas of the benign and malignant breast lesions taken into exam. Conversely, protein p16 expression, although heterogeneously distributed within the section, is considerably higher in breast carcinoma as compared to fibroadenoma in both tumoral and non-tumoral epithelia and stroma. The protein localization was almost exclusively nuclear in fibroadenoma and non-tumoral epithelia whereas, in carcinoma, the staining was both nuclear and cytoplasmic or cytoplasmic alone. Furthermore, in a subset of fibroadenoma with higher proliferative activity, p16 protein expression was substantially decreased as compared to those showing lower proliferation. We did not observe this association in carcinomas. Our data demonstrate that the hypermethylation of the p16INK4a promoter is not specifically associated with malignancy and that, on the contrary, the overexpression of p16 and its cytoplasmic sequestration is a feature of breast carcinoma.Keywords
This publication has 24 references indexed in Scilit:
- Electron microscopy evidence that cytoplasmic localization of the p16INK4A“nuclear” cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomasBiotechnic & Histochemistry, 2004
- Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanismsThe Journal of Pathology, 2003
- Expression and methylation of CASP8 in neuroblastoma: Identification of a promoter regionNature Medicine, 2002
- MeCP2 and MBD2 expression during normal and pathological growth of the human mammary glandOncogene, 2002
- Quantitative Assessment of Promoter Hypermethylation during Breast Cancer DevelopmentThe American Journal of Pathology, 2002
- Methylation-independent silencing of the p73 gene in neuroblastomaOncogene, 2000
- Cancer Cell CyclesScience, 1996
- Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibitionNature, 1995
- Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors.Proceedings of the National Academy of Sciences, 1995
- A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor TypesScience, 1994